Evidence brief · printable

Dermatomyositis evidence brief

One page, every section sourced. Print it or bring it on your phone.

Print or save as PDF Fits on one A4 or Letter page.

Dermatomyositis: evidence brief

Open Source Medicine Foundation · page built 16 November 2026 · trial data searched 2026-11-16 · https://research.opensourcemed.info/briefs/dermatomyositis.html

Research information, not medical advice. Prepared to support a conversation with a clinician, not to choose a treatment.

Live version

Medicines with registered trials

Scale: trials listed for each medicine on the tracker's condition page, a snapshot of ClinicalTrials.gov. A trial means it is being studied, not that it works.

  • Cyclophosphamide 3 trials
  • Fludarabine 3 trials
  • Anti-CD19 CAR T cell therapy 2 trials
  • Baricitinib 2 trials
  • Etanercept 2 trials
  • 3'mRNA sequencing 1 trial

Non-drug approaches tested

Scale: trial status on ClinicalTrials.gov (completed, results posted). Status is not a result.

  • Education, coaching and self-management 1 trials · 1 completed · 0 with results
  • Resistance and strength training 1 trials · 1 completed · 0 with results
  • Other behavioural interventions 3 trials · 1 completed · 0 with results
  • Other supplements and nutraceuticals 1 trials · 1 completed · 0 with results

Trials recruiting

Status as recorded on ClinicalTrials.gov when searched (2026-11-16); check the registry for current status and eligibility.

  • Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis NCT06857240
  • FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM) NCT07111065
  • Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study NCT07486869
Sources: ClinicalTrials.gov (trials, status, posted results); RepurpOS natural-product tiers (registry trials, PubMed, reference databases); OSMF biomarker atlas where available; OSMF non-drug evidence map (9 non-drug trials for this condition). Lists are shortened; the live pages carry every entry with its source: evidence-gap map · RepurpOS · condition page. Counts change daily. Nothing here is a recommendation to start, stop or change any treatment.